期刊文献+

紫杉醇MPEG-PCL纳米粒的制备、表征及其体外释药行为研究 被引量:3

Paclitaxel/MPEG-PCL Nanoparticles: Preparation, Characterization and in Vitro Release
原文传递
导出
摘要 目的以聚乙二醇单甲醚-聚己内酯(MPEG-PCL)为载体制备紫杉醇MPEG-PCL纳米粒并对其体外释放行为进行考察。方法采用开环聚合法合成MPEG-PCL共聚物,采用核磁共振波谱仪(1H-NMR)、傅里叶红外光谱仪(FTIR)对其进行表征;通过共沉淀法制备了紫杉醇MPEG-PCL纳米粒,并测定了粒径分布、Zeta电位、结构特征、包封率以及载药量;同时以磷酸盐缓冲溶液(pH=7.4)为释放介质考察其体外释放行为。结果成功合成了相对分子质量为4 875的MPEG-PCL共聚物。透射电镜结果显示紫杉醇MPEG-PCL纳米粒具有规则的球形结构,纳米粒的平均粒径为(102.3±3.5)nm,PDI=0.102,药物包封率和载药量分别为(95.6±3.2)%和(8.5±0.4)%。体外释放结果显示紫杉醇可以缓慢的从MPEG-PCL纳米粒中释放出来。结论 MPEG-PCL共聚物是紫杉醇的良好载体,所制备的纳米粒具有包封率和载药量高、药物释放缓慢的特点。 OBJECTIVE To develop paclitaxeI(PTX)/MPEG-PCL nanoparticles and investigate its in vitro release behavior METHODS MPEG-PCL block polymer was synthesized by a ring-opeing polymerization method, followed by the characterization with 1H-NMR and FTIR. The PTX/MPEG-PCL nanoparticles was firstly prepared by a coprecipitation method, and then characterized by a DLS, TEM and etc. In vitro release study of PTX/MPEG-PCL nanoparticles as a function with time was performed in PBS solution (pH=7.4) at 37℃. RESULTS With the analysis of 1H-NMR and FTIR spectrum, MPEG-PCL block polymer (molecular weight=4 875) was successfully synthesized. With the observation of TEM, the developed PTX/MPEG-PCL nanoparticles showed almost spherical in shape with uniform mean particle size about (102.3±3.5)nm. Drug loading effciency and drug loading capacity of PTX/MPEG-PCL nanoparticles were (95.6±3.2)% and (8.5±0.4)%, respectively. In vitro release study indicated that PTX was released in a sustained-release manner from MPEG-PCL nanoparticles. CONCLUSION MPEG-PCL nanoparticle as an excellent carrier for PTX exhibits high drug loading effciency, drug loading capacity and sustained release progerty.
出处 《中国现代应用药学》 CAS CSCD 2014年第9期1093-1097,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 聚乙二醇单甲醚-聚己内酯 纳米粒 紫杉醇 体外释放 MPEG-PCL nanoparticle paclitaxel in vitro release
  • 相关文献

参考文献12

  • 1LAI D, HO K C, HAO Y, et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF [J]. Cancer Res, 2011, 71(7): 2728-2738.
  • 2ALI I, RAHIS-UDDIN SALIM K, et al. Advances in nano drugs for cancer chemotherapy [J]. Curr Cancer Drug Targets, 2011, 11(2): 135-146.
  • 3CARUTHERS S D, WICKLINE S A, LANZA G M. Nanotechnological applications in medicine [J]. Curr Opin Biotechnol, 2007, 18(1): 26-30.
  • 4GOU M, ZHENG X, MEN K, et al. Self-assembled hydrophobic honokiol loaded MPEG-PCL diblock copolymer micelles [J]. Pharm Res, 2009, 26(9): 2164-2173.
  • 5HYUN H, KIM Y H, SONG I B, et al. In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier [J]. Biomacromolecules, 2007, 8(4): 1093-1100.
  • 6LI X, ZHANG Z, LI J, et al. Diclofenac/biodegradable polymer micelles for ocular applications [J]. Nanoscale, 2012, 4(15): 4667-4673.
  • 7MOON S K, KWANG S S, GILSON K, et al. Ring-opening polymerization of ε-aprolactone by poly (ethylene glycol) by an activated monomer mechanism [J]. Macromol Rapid Commun, 2005, 26(8): 643-648.
  • 8SOSNIK A, COHN D. Poly (ethylene glycol)-poly (epsilon- caprolactone) block oligomers as injectable materials [J]. Polymer, 2003, 44(23): 7033-7042.
  • 9LIU Y, NGUYEN J, STEELE T, et al. A new synthesis method and degradation of hyper-branched polyethylenimine grafted polycaprolactone block mono-methoxyl poly (ethylene glycol) copolymers (hy-PEI-g-PCL-b-mPEG) as potential DNA delivery vectors [J]. Polymer, 2009, 50(16): 3895-3904.
  • 10KANG Y M, LEE S H, LEE J Y, et al. A biodegradable, injectable, gel system based on MPEG-b-(PCL-ran-PLLA) diblock copolymers with an adjustable therapeutic window [J]. Biomaterials, 2010, 31(9): 2453-2460.

同被引文献20

  • 1张晓君,王东凯,韩晓.聚合物胶束作为药物传递系统的研究进展[J].中国药剂学杂志(网络版),2009(3):177-183. 被引量:18
  • 2中国药典.四部[S].2015:202.
  • 3SCHIFF P B, FANT J, HORWITZ S B. Promotion of microtubule assembly in vitro by taxol [J]. Nature, 1979, 277(5698): 665-667.
  • 4SINGLA A K, GARG A, AGGARWAL D. Paclitaxel and its formulations [J]. Int J Pharrn, 2002, 235(1): 179-192.
  • 5DORR R T. Pharmacology and toxicology of Cremophor EL diluent [J]. Ann Pharmacother, 1994, 28(5): S1 I-S14.
  • 6NAGARWAL R C, KUMAR R, DHANAWAT M, et al. Nanocrystal technology in the delivery of poorly soluble drugsan overview [J]. Curt Drug Deliv, 2011, 8(4): 398-406.
  • 7VAN EERDENBRUGH B, VAN DEN MOOTER G, AUGUSTIJNS P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products [J]. Int J Pharm, 2008, 364(1): 64-75.
  • 8RABINOW B E. Nanosuspensions in drug delivery [J]. Nat Rev Drug Discov, 2004, 3(9): 785-796.
  • 9WONG J, BRUGGER A, KHARE A, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects [J]. Adv Drug Deliv Rev, 2008, 60(8): 939-954.
  • 10郭东艳,陈士林,杨大坚.葛根素衍生物4ac混悬液及其纳米粒在Beagle犬体内的药代动力学研究[J].时珍国医国药,2009,20(1):197-198. 被引量:9

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部